Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Dr. Reddy's delivered a strong Q4 FY24 with revenue of INR 7,083 crore (+12% YoY) and EBITDA of INR 1,872 crore (+15% YoY), driven by robust North America generics growth (+26% YoY to $392M) and market share expansion. PAT surged 36% YoY to INR 1,307 crore, aided by a lower effective tax rate. The company reported all-time high full-year revenue of $3.3B and EBITDA margin of 29.7%. Management guided for sustained double-digit growth in emerging markets and India (ex-divestments), with R&D spend of 8.5%-9% of sales. Key strategic moves include the Nestlé JV for consumer health (contributing post-FY27) and a partnership with Sanofi for vaccines. Risks include price erosion in select US products and forex volatility in emerging markets.
डॉ. रेड्डीज ने वित्त वर्ष 2024 की चौथी तिमाही में शानदार प्रदर्शन किया। कंपनी की कमाई 7,083 करोड़ रुपये रही, जो पिछले साल से 12% ज्यादा है। मुनाफा 1,307 करोड़ रुपये रहा, जो 36% बढ़ा। इसकी वजह अमेरिका में जेनेरिक दवाओं की बिक्री में 26% का उछाल और कम टैक्स दर थी। पूरे साल की कमाई 3.3 अरब डॉलर रही, जो अब तक की सबसे ज्यादा है। कंपनी का कहना है कि उभरते बाजारों और भारत में दोहरे अंकों की बढ़त जारी रहेगी। नेस्ले के साथ मिलकर उपभोक्ता स्वास्थ्य उत्पाद बनाएंगे और सनोफी के साथ वैक्सीन बनाने का समझौता किया है। जोखिमों में अमेरिका में कुछ दवाओं की कीमत गिरना और विदेशी मुद्रा में उतार-चढ़ाव शामिल है।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Price erosion in US generics
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
North America Generics Revenue
$392M
+26% YoY
Driven by market share expansion in key products and acquired brand portfolio.
India Business Growth (ex-divestments)
11%
+11% YoY
Double-digit growth in Q4, excluding income from brands divested last year.
R&D Spend as % of Sales
9.7%
+119bps YoY
Higher R&D investment driven by biosimilar pipeline and complex generics.
New Product Launches in US (FY24)
21
N/A
Launched 21 products in FY24; expects similar momentum in FY25 with 20+ launches.
What Changed vs Last Quarter
NEW
R&D spend to be 8.5%-9% of sales in FY25
Management expects R&D investment to remain in the 8.5%-9% range, with fluctuations based on clinical trial timing.
NEW
Nestlé JV to contribute post-FY27
The joint venture with Nestlé will require initial investment and brand registration; meaningful revenue contribution expected after FY27.
NEW
First meaningful biosimilar launch in FY27
Internal biosimilar pipeline expected to yield first product launch in Europe and US in FY27, with profitability thereafter.
UPDATED
India business to grow double-digit in FY25
Excluding divestment income, India business is expected to continue double-digit growth, driven by new product launches and partnerships.
DROPPED
26 meaningful US launches over FY25-26
Approximately 26 products with potential sales >$10M each are expected to launch in the US over the next two years, subject to approvals.
DROPPED
Six biosimilars targeting first-to-market by FY30
Biosimilar pipeline includes six products aiming for first-to-market status, with first launch expected in early CY2027.
DROPPED
SG&A investments to continue at elevated levels
SG&A spend will remain higher in absolute terms as investments in brands and pipeline products continue, with revenue growth expected to provide operating leverage.
NEW RISK
Forex volatility in emerging markets
Emerging market growth in constant currency may be offset by unfavorable forex movements, particularly in Russia and other markets.
NEW RISK
Biosimilar Rituximab CRL delays
US FDA issued a complete response letter for biosimilar Rituximab due to CMC questions; resolution expected around September, but timeline for approval remains uncertain.
NEW RISK
Competition in Revlimid generic
Multiple new entrants in the generic Revlimid market could impact pricing and volume, though management declined to discuss specifics.
RISK GONE
Potential OAI outcome at FTO-3 facility
FDA issued Form 483 with 10 observations at FTO-3; management has responded but risk of OAI classification could impact approvals and reputation.
RISK GONE
Dependence on Revlimid for cash flows
Revlimid contribution remains meaningful; any unexpected decline could impact cash generation and ability to invest in pipeline.
RISK GONE
Supply chain disruptions from Red Sea crisis
Geopolitical tensions are causing sea route disruptions; management is building inventory but costs could rise if situation persists.
Fast read
Guidance and risk preview
Management expects R&D investment to remain in the 8.5%-9% range, with fluctuations based on clinical trial timing.
Management acknowledged price erosion on select large products, partially offset by other products.
View Risks →